Literature DB >> 24029126

Central nervous system cancers.

Louis Burt Nabors, Mario Ammirati, Philip J Bierman, Henry Brem, Nicholas Butowski, Marc C Chamberlain, Lisa M DeAngelis, Robert A Fenstermaker, Allan Friedman, Mark R Gilbert, Deneen Hesser, Matthias Holdhoff, Larry Junck, Ronald Lawson, Jay S Loeffler, Moshe H Maor, Paul L Moots, Tara Morrison, Maciej M Mrugala, Herbert B Newton, Jana Portnow, Jeffrey J Raizer, Lawrence Recht, Dennis C Shrieve, Allen K Sills, David Tran, Nam Tran, Frank D Vrionis, Patrick Y Wen, Nicole McMillian, Maria Ho.   

Abstract

Primary and metastatic tumors of the central nervous system are a heterogeneous group of neoplasms with varied outcomes and management strategies. Recently, improved survival observed in 2 randomized clinical trials established combined chemotherapy and radiation as the new standard for treating patients with pure or mixed anaplastic oligodendroglioma harboring the 1p/19q codeletion. For metastatic disease, increasing evidence supports the efficacy of stereotactic radiosurgery in treating patients with multiple metastatic lesions but low overall tumor volume. These guidelines provide recommendations on the diagnosis and management of this group of diseases based on clinical evidence and panel consensus. This version includes expert advice on the management of low-grade infiltrative astrocytomas, oligodendrogliomas, anaplastic gliomas, glioblastomas, medulloblastomas, supratentorial primitive neuroectodermal tumors, and brain metastases. The full online version, available at NCCN. org, contains recommendations on additional subtypes.

Entities:  

Mesh:

Year:  2013        PMID: 24029126      PMCID: PMC4124889          DOI: 10.6004/jnccn.2013.0132

Source DB:  PubMed          Journal:  J Natl Compr Canc Netw        ISSN: 1540-1405            Impact factor:   11.908


  171 in total

Review 1.  Recent developments in the molecular characterization and treatment of oligodendroglial tumors.

Authors:  Martin van den Bent; Olivier-Louis Chinot; J Gregory Cairncross
Journal:  Neuro Oncol       Date:  2003-04       Impact factor: 12.300

2.  Survival and functional status after resection of recurrent glioblastoma multiforme.

Authors:  F G Barker; S M Chang; P H Gutin; M K Malec; M W McDermott; M D Prados; C B Wilson
Journal:  Neurosurgery       Date:  1998-04       Impact factor: 4.654

3.  NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality.

Authors:  Roger Stupp; Eric T Wong; Andrew A Kanner; David Steinberg; Herbert Engelhard; Volkmar Heidecke; Eilon D Kirson; Sophie Taillibert; Frank Liebermann; Vladimir Dbalý; Zvi Ram; J Lee Villano; Nikolai Rainov; Uri Weinberg; David Schiff; Lara Kunschner; Jeffrey Raizer; Jerome Honnorat; Andrew Sloan; Mark Malkin; Joseph C Landolfi; Franz Payer; Maximilian Mehdorn; Robert J Weil; Susan C Pannullo; Manfred Westphal; Martin Smrcka; Lawrence Chin; Herwig Kostron; Silvia Hofer; Jeffrey Bruce; Rees Cosgrove; Nina Paleologous; Yoram Palti; Philip H Gutin
Journal:  Eur J Cancer       Date:  2012-05-18       Impact factor: 9.162

4.  Temozolomide as an alternative to irradiation for elderly patients with newly diagnosed malignant gliomas.

Authors:  Michael Glantz; Marc Chamberlain; Qin Liu; N Scott Litofsky; Lawrence D Recht
Journal:  Cancer       Date:  2003-05-01       Impact factor: 6.860

5.  Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma.

Authors:  Wolfgang Wick; Vinay K Puduvalli; Marc C Chamberlain; Martin J van den Bent; Antoine F Carpentier; Lawrence M Cher; Warren Mason; Michael Weller; Shengyan Hong; Luna Musib; Astra M Liepa; Donald E Thornton; Howard A Fine
Journal:  J Clin Oncol       Date:  2010-02-01       Impact factor: 44.544

6.  Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors.

Authors:  Maria Möllemann; Marietta Wolter; Jörg Felsberg; V Peter Collins; Guido Reifenberger
Journal:  Int J Cancer       Date:  2005-01-20       Impact factor: 7.396

7.  Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome.

Authors:  G Kaloshi; A Benouaich-Amiel; F Diakite; S Taillibert; J Lejeune; F Laigle-Donadey; M-A Renard; W Iraqi; A Idbaih; S Paris; L Capelle; H Duffau; P Cornu; J-M Simon; K Mokhtari; M Polivka; A Omuro; A Carpentier; M Sanson; J-Y Delattre; K Hoang-Xuan
Journal:  Neurology       Date:  2007-05-22       Impact factor: 9.910

8.  Seizure characteristics and control following resection in 332 patients with low-grade gliomas.

Authors:  Edward F Chang; Matthew B Potts; G Evren Keles; Kathleen R Lamborn; Susan M Chang; Nicholas M Barbaro; Mitchel S Berger
Journal:  J Neurosurg       Date:  2008-02       Impact factor: 5.115

9.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma in elderly patients.

Authors:  G Minniti; V De Sanctis; R Muni; F Filippone; A Bozzao; M Valeriani; M F Osti; U De Paula; G Lanzetta; V Tombolini; R Maurizi Enrici
Journal:  J Neurooncol       Date:  2008-02-05       Impact factor: 4.130

10.  Thirty years' experience with Gamma Knife surgery for metastases to the brain.

Authors:  Bengt Karlsson; Patrick Hanssens; Robert Wolff; Michael Söderman; Christer Lindquist; Guus Beute
Journal:  J Neurosurg       Date:  2009-09       Impact factor: 5.115

View more
  22 in total

1.  PD-1/PD-L1 and immune-related gene expression pattern in pediatric malignant brain tumors: clinical correlation with survival data in Korean population.

Authors:  Kihwan Hwang; Eun Jung Koh; Eun Jin Choi; Tae Hee Kang; Jung Ho Han; Gheeyoung Choe; Sung-Hye Park; Jennifer Holmes Yearley; Lakshmanan Annamalai; Wendy Blumenschein; Manjiri Sathe; Terri McClanahan; Hun Jung; Kyu-Chang Wang; Seung-Ki Kim; Chae-Yong Kim
Journal:  J Neurooncol       Date:  2018-05-05       Impact factor: 4.130

2.  Salvage therapy with lomustine for temozolomide refractory recurrent anaplastic astrocytoma: a retrospective study.

Authors:  Marc C Chamberlain
Journal:  J Neurooncol       Date:  2015-01-07       Impact factor: 4.130

3.  Multimodal Imaging in Malignant Brain Tumors: Enhancing the Preoperative Risk Evaluation for Motor Deficits with a Combined Hybrid MRI-PET and Navigated Transcranial Magnetic Stimulation Approach.

Authors:  V Neuschmelting; C Weiss Lucas; G Stoffels; A-M Oros-Peusquens; H Lockau; N J Shah; K-J Langen; R Goldbrunner; C Grefkes
Journal:  AJNR Am J Neuroradiol       Date:  2015-10-29       Impact factor: 3.825

Review 4.  Oncological Ligand-Target Binding Systems and Developmental Approaches for Cancer Theranostics.

Authors:  Jaison Jeevanandam; Godfred Sabbih; Kei X Tan; Michael K Danquah
Journal:  Mol Biotechnol       Date:  2021-01-09       Impact factor: 2.695

Review 5.  Fractionated stereotactic radiation therapy for brain metastases: a systematic review with tumour control probability modelling.

Authors:  Sujith Baliga; Madhur K Garg; Jana Fox; Shalom Kalnicki; Patrick A Lasala; Mary R Welch; Wolfgang A Tomé; Nitin Ohri
Journal:  Br J Radiol       Date:  2016-12-12       Impact factor: 3.039

6.  Validation and Development of a Modified Breast Graded Prognostic Assessment As a Tool for Survival in Patients With Breast Cancer and Brain Metastases.

Authors:  Ishwaria M Subbiah; Xiudong Lei; Jeffrey S Weinberg; Erik P Sulman; Mariana Chavez-MacGregor; Debu Tripathy; Rohan Gupta; Ankur Varma; Jay Chouhan; Richard P Guevarra; Vicente Valero; Mark R Gilbert; Ana M Gonzalez-Angulo
Journal:  J Clin Oncol       Date:  2015-05-18       Impact factor: 44.544

7.  Salvage therapy with bendamustine for temozolomide refractory recurrent anaplastic gliomas: a prospective phase II trial.

Authors:  Marc C Chamberlain; Howard Colman; Bryan T Kim; Jeffrey Raizer
Journal:  J Neurooncol       Date:  2017-02-16       Impact factor: 4.130

8.  Magnetic resonance image features identify glioblastoma phenotypic subtypes with distinct molecular pathway activities.

Authors:  Haruka Itakura; Achal S Achrol; Lex A Mitchell; Joshua J Loya; Tiffany Liu; Erick M Westbroek; Abdullah H Feroze; Scott Rodriguez; Sebastian Echegaray; Tej D Azad; Kristen W Yeom; Sandy Napel; Daniel L Rubin; Steven D Chang; Griffith R Harsh; Olivier Gevaert
Journal:  Sci Transl Med       Date:  2015-09-02       Impact factor: 17.956

9.  Multicenter phase 2 study of patupilone for recurrent or progressive brain metastases from non-small cell lung cancer.

Authors:  Lakshmi Nayak; Lisa M DeAngelis; H Ian Robins; Ramaswamy Govindan; Shirish Gadgeel; Karen Kelly; James R Rigas; David M Peereboom; Steven S Rosenfeld; Alona Muzikansky; Ming Zheng; Patrick Urban; Lauren E Abrey; Antonio Omuro; Patrick Y Wen
Journal:  Cancer       Date:  2015-08-26       Impact factor: 6.860

Review 10.  Glioma virus therapies between bench and bedside.

Authors:  Johanna K Kaufmann; E Antonio Chiocca
Journal:  Neuro Oncol       Date:  2014-01-26       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.